KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Long-Term Investments (2017 - 2024)

Arbutus Biopharma's Long-Term Investments history spans 9 years, with the latest figure at $3.0 million for Q3 2024.

  • For Q3 2024, Long-Term Investments changed N/A year-over-year to $3.0 million; the TTM value through Sep 2024 reached $3.0 million, changed N/A, while the annual FY2021 figure was $35.7 million, N/A changed from the prior year.
  • Long-Term Investments for Q3 2024 was $3.0 million at Arbutus Biopharma, down from $11.1 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $37.4 million in Q1 2022 and bottomed at $3.0 million in Q3 2024.
  • The 5-year median for Long-Term Investments is $35.7 million (2021), against an average of $24.7 million.
  • The largest annual shift saw Long-Term Investments crashed 81.81% in 2020 before it skyrocketed 1010.05% in 2021.
  • A 5-year view of Long-Term Investments shows it stood at $3.2 million in 2020, then surged by 1010.05% to $35.7 million in 2021, then grew by 4.69% to $37.4 million in 2022, then crashed by 70.41% to $11.1 million in 2023, then tumbled by 73.19% to $3.0 million in 2024.
  • Per Business Quant, the three most recent readings for ABUS's Long-Term Investments are $3.0 million (Q3 2024), $11.1 million (Q2 2023), and $37.4 million (Q1 2022).